EgertonUniOHC/AMR

Focused conversations on Antimicrobial Resistance (AMR) and Infection Prevention and Control (IPC).
Youth-led. Evidence-based. One Health-driven.

[EgertonUniOHC/AMR @EUOHC_AMR]

Antibiotics, when they first came around, were called Miracle cures. There had never existed a thing like them. A pill could now easily reverse what initially had been a declaration of death. We literally doubled our life expectancies... /1

[CoELIB @CoELIB_Egerton]

Madaraka Day is a reminder that true progress is built when people have the freedom to create, innovate, trade, and pursue their aspirations.

[johanna @mikobadr79]

@KennyCarmody
Thank you for sharing and addressing mitochondrial dysfunction and its huge role in disease ... this is such an important topic.
Fluoroquinolones are among the worst offenders when it comes to drug-induced mitochondrial damage (DIMD), and I’m genuinely happy to see more people speaking up about how serious it is.
I’ve been sharing resources and my own experience with this for at https://t.co/oSl7OWfCF4. Keep shining a light on mitochondrial health 🙏
I am going to check out this book, thank you

[EgertonUniOHC/AMR @EUOHC_AMR]

🇰🇪

[EgertonUniOHC/AMR @EUOHC_AMR]

If only the math worked differently.

#AntimicrobialResistance #AMR #Pharma #PublicHealth #GlobalHealth #Antibiotics

[EgertonUniOHC/AMR @EUOHC_AMR]

PART TWO: THE DRUGS WE'LL NEVER SEE
Right now, in laboratories around the world, there are probably dozens of promising antibiotic candidates. Compounds that could fight resistant gonorrhea, treat carbapenem-resistant Enterobacteriaceae. Novel agents that could give us hope

[EgertonUniOHC/AMR @EUOHC_AMR]

Meanwhile, a single cancer drug, Keytruda, made over $17 billion in sales in 2021 alone. (PS: it made more than Tetraphase Pharma was sold for). The market has spoken, and it's saying: Don't make antibiotics. All these comprise THE DRUGS WE WILL NEVER SEE.

(Coming in PART TWO)

[EgertonUniOHC/AMR @EUOHC_AMR]

millions will never be made. Not because we can't make them, but because we have built a world where it doesn't pay to try. This is the antibiotic crisis nobody talks about. Not just the resistance, but absence of the treatments that could have been lives that mightve been saved.

[Anish Moonka @anishmoonka]

Scientists put people on a 12-week exercise program and measured how old their bodies looked at the cellular level. After 12 weeks, their cells tested 10 months younger. That's from a 2026 study of over 45,000 people. Not slower aging. Younger.

Sinclair's four words each trigger a completely different chain reaction in the body. I dug through the research on all four.

Walking has the deepest evidence base. A 2025 review of 57 studies found that 7,000 steps per day reduced the risk of early death by roughly 47%. Every extra 1,000 steps lowered it by another 15%, based on data from 227,000 people. How you walk matters too. A study of 33,560 adults found that people who walked in uninterrupted 15-minute sessions had a death risk of 0.80% over 9.5 years. People who took the same number of steps in scattered bursts under 5 minutes? 4.36%. Same steps, five times the risk.

Running hits the brain hardest. The part of your brain responsible for memory (the hippocampus) shrinks 1 to 2% per year after age 50. That's one reason memory fades. But a trial at the University of Pittsburgh put 120 older adults on a one-year running program, and their hippocampus actually grew by 2%, reversing 1 to 2 years of brain shrinkage. How it works: when you run, your muscles release a chemical that travels into the brain and triggers the production of BDNF, a protein that acts like fertilizer for brain cells. It literally causes new neurons to grow. Mice that had this chemical genetically removed got zero brain benefits from running, even with the same mileage.

Lifting carries its own death-risk data. A review of 10 studies found that any amount of weight training lowered death risk by 15%, heart disease death by 19%, and cancer death by 14%. The sweet spot was about 60 minutes per week, at which the risk dropped by 27%. What caught my attention: combining lifting with cardio dropped death risk by 40% in a separate review of 370,000 people. Lifting alone, with zero cardio, showed no survival benefit in one large study of 216,000 older adults. The two need each other.

Stretching is the one nobody takes seriously. A 2024 study followed 3,139 people aged 46 to 65 for nearly 13 years, measuring flexibility across seven joints. Men with the stiffest bodies were 1.87x more likely to die during the study. For women, 4.78x. The likely reason is that flexible joints share the same structural materials as your arteries. Stiff joints often mean stiff blood vessels. Flexibility also predicts fall risk, which is one of the top causes of death in older adults.

Underneath all four, one shared mechanism keeps showing up. Exercise activates your cells' built-in recycling system (scientists call it autophagy). When you move hard, your cells start breaking down damaged parts, worn-out power generators, and accumulated junk, then reuse the raw materials to build fresh components. A 2016 Nobel Prize was awarded for discovering how this system works. People who live past 100 show significantly higher levels of this cellular cleanup than people the same age who die earlier. And in animal studies, when researchers silenced the genes responsible for this recycling, exercise no longer extended lifespan. The longevity benefit of movement runs through this one cleanup process.

Four words in the tweet. Four distinct biological pathways, each doing something the others can't.

[EgertonUniOHC/AMR @EUOHC_AMR]

Meanwhile, a single cancer drug, Keytruda, made over $17 billion in sales in 2021 alone. (PS: it made more than Tetraphase Pharma was sold for). The market has spoken, and it's saying: Don't make antibiotics. All these comprise THE DRUGS WE WILL NEVER SEE.

(Coming in PART TWO)

[EgertonUniOHC/AMR @EUOHC_AMR]

THE ANTIBIOTICS THAT NEVER WERE

Why Pharmaceutical Companies Won't Save Us From Superbugs

In a boardroom somewhere in Basel, Switzerland, executives at a major pharmaceutical company are reviewing their pipeline. Twenty three drug candidates are in various stages of development

[EgertonUniOHC/AMR @EUOHC_AMR]

it as reserve for only the most serious cases. A life-saving antibiotic, approved by the FDA to run its manufacturer bankrupt. And does it stop? No. Look up for how much Tetraphase Pharmaceuticals was sold after it successfully designed eravacycline for resistant infections.